Get the Stockscreener App
54.95
4.53%
-2.61
After Hours:
54.95
Akero Therapeutics Inc Stock (AKRO) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation - Markets Insider
Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 10,000 Shares of Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - Markets Insider
This Stock Just Doubled in 1 Day -- Is It Still a Buy? - MSN
Akero Therapeutics COO Jonathan Young sells shares worth $538,060 By Investing.com - Investing.com South Africa
Akero Therapeutics Insider Sold Shares Worth $538,061, According to a Recent SEC Filing - Marketscreener.com
Akero Therapeutics COO Jonathan Young sells shares worth $538,060 - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out - Markets Insider
Akero Shares Skyrocket as MASH Drug Delivers Game-Changing Results - MSN
Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025 - MSN
(AKRO) Investment Analysis and Advice - Stock Traders Daily
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - Markets Insider
5 Stocks That Started The Year On A High - Insider Monkey
Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High - Insider Monkey
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 5,000 Shares - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect - Markets Insider
Akero Therapeutics (NASDAQ:AKRO) Upgraded at Bank of America - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 31,250 Shares - MarketBeat
Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now? - Yahoo Finance
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio? - Benzinga
UBS Group Raises Akero Therapeutics (NASDAQ:AKRO) Price Target to $109.00 - Defense World
Equities Analysts Issue Forecasts for AKRO FY2029 Earnings - MarketBeat
UBS Group Issues Positive Forecast for Akero Therapeutics (NASDAQ:AKRO) Stock Price - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Stock Rating Upgraded by Bank of America - Defense World
Canaccord Genuity Group Forecasts Strong Price Appreciation for Akero Therapeutics (NASDAQ:AKRO) Stock - MarketBeat
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Akero Therapeutics chief development officer sells shares worth $3.01 million - Investing.com India
Akero Therapeutics chief development officer sells shares worth $3.01 million By Investing.com - Investing.com South Africa
Akero Therapeutics chief development officer sells $2.73 million in stock - Investing.com India
Akero Therapeutics chief development officer sells $2.73 million in stock By Investing.com - Investing.com South Africa
Why did Akero (AKRO) stock soar 110% on Monday? - MSN
Akero Therapeutics (NASDAQ:AKRO) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World
Akero Therapeutics price target raised to $73 from $56 at Canaccord - MSN
Andrew Cheng Sells 30,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Akero raised to Buy at Bank of America after liver drug data - MSN
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance
Akero stock raised to Buy at Bank of America (AKRO:NASDAQ) - Seeking Alpha
Akero Therapeutic prices upsized stock offering of $350M - MSN
Akero Therapeutics (NASDAQ:AKRO) Trading 4.8% Higher After Analyst Upgrade - MarketBeat
Akero Therapeutics senior VP sells $285,150 in stock - MSN
Akero Therapeutics shares soar on positive study results - MSN
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
BofA Securities Upgrades Akero Therapeutics to Buy, $63 Price Target -January 30, 2025 at 07:46 am EST - Marketscreener.com
Morgan Stanley Forecasts Strong Price Appreciation for Akero Therapeutics (NASDAQ:AKRO) Stock - Defense World
Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 4.8% Following Analyst Upgrade - Defense World
Akero Therapeutics (NASDAQ:AKRO) Stock Price Expected to Rise, Citigroup Analyst Says - Defense World
Akero Therapeutics CEO Andrew Cheng sells $1.65 million in stock - MSN
Akero Therapeutics senior VP sells $285,150 in stock By Investing.com - Investing.com Australia
Akero Therapeutics' chief scientific officer sells $1.74 million in stock - MSN
Akero Therapeutics Stock Doubles on Liver Data - MSN
Akero Therapeutics announces proposed public offering of common stock - MSN
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):